Study co-authors include Virginia Wadley, PhD, Mary Cushman, Frederick Unverzagt, PhD, Neil Zakai, MD, Brett Kissela, MD, David Warnock, MD, and William McClellan, MD (for the REGARDS Study Group, University of Alabama at Birmingham).
Disclosures: The study received pharmaceutical company support in addition to funding from the National Institute of Neurological Disorders and Stroke. Dr. Cushman is a consultant for Glaxo Smith Kline and receives grants/research support from Amgen. Dr. Unverzagt holds ownership in Eli Lilly. Dr. Warnock is a consultant for Genzyme and Gilhead, holds ownership in Parion and Relypsa, and receives honoraria from Genzyme, Amicus, Amgen, Gilhead, and Shire. Dr. McClellan receives grant/research support from and is a scientific advisor for Amgen. Dr. Wadley, Dr. Zakai, and Dr. Kissela reported no financial disclosures.
The study abstract, "Albuminuria, Kidney Function and the Incidence of Cognitive Impairment in US Adults," [SA-FC359] will be presented as an oral presentation on Saturday, November 20 Day, Date at 6:06 PM MT in Room 405 of the Colorado Convention Center in Denver, CO.
|Contact: Shari Leventhal|
American Society of Nephrology